Common Genetic Variation Linked to Response to Antidepressants

February 15, 2012 · Posted in Risk Factors 

DNA strandBrain-derived neurotrophic factor (BDNF) protects neurons and is important for long-term learning and memory. There are several genetic variations in BDNF depending on which amino acid—valine or methionine—falls at a particular position when the proBDNF protein is being made.  Most people have the val-66-val allele, some have the val-66-met, and a few have the met-66-met allele.

Researcher Jessica C. Levenson, working with David Kupfer and Ellen Frank at the University of Pittsburgh, reported at the 51st Annual Meeting of the National Institute of Mental Health’s New Clinical Drug Evaluation Unit (NCDEU) in 2011 that patients with unipolar depression who have the val-66-val allele of proBDNF have better clinical responsiveness to antidepressants than those with the slightly less common variant, val-66-met.

Editor’s note: The val-66-val allele is more effective in enhancing synaptic plasticity and is more easily transported from the nucleus to the dendrites of neurons (where it is necessary for learning and memory) than the val-66-met allele or the least effective met-66-met variant.

These findings are intriguing because antidepressant treatments tend to increase BDNF, regardless of their mechanisms of action. Moreover, BDNF levels are low in patients with depression, usually in direct relationship to the severity of depression. Thus, the ability of antidepressants to increase BDNF may lead to a more effective treatment response in those with the better functioning val-66-val allele of BDNF. This remains to be further documented, but the study provides a preliminary example of how genotyping may eventually be able to help predict individual clinical response to a given treatment and thus foster the development of personalized medicine.

Comments

Leave a Reply


Notice: Undefined variable: user_ID in /home/bipolarn/public_html/wp-content/themes/black-lucas/comments.php on line 78